Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts. Show more

Location: 1560 Trapelo Road, Waltham, MA, 02451, United States | Website: https://www.dyne-tx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.599B

52 Wk Range

$6.36 - $47.45

Previous Close

$11.24

Open

$11.34

Volume

2,268,165

Day Range

$11.17 - $11.76

Enterprise Value

1.036B

Cash

683.9M

Avg Qtr Burn

-89.89M

Insider Ownership

0.49%

Institutional Own.

91.29%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.